Mirador Therapeutics, Inc.
Clinical trials sponsored by Mirador Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug pair safely with a known Anti-Inflammatory? a trial investigates Results expected Nov 2026 (estimated)
- New drug MT-201 tested in humans for first time Results expected Nov 2026 (estimated)
- New drug MT-251 tested in healthy people for first time Results expected Mar 2027 (estimated)
- New hope for IBD sufferers: two experimental drugs enter Mid-Stage trial Results expected Apr 2027 (estimated)
-
New hope for IBD sufferers: two experimental drugs enter Mid-Stage trial
Disease control Recruiting nowThis Phase 2 study is testing two new drugs, MT-501 and MT-201, in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The goal is to see if these treatments are safe and can improve symptoms and gut healing. Researchers will monitor side effects and measure…
Phase 2 • Sponsor: Mirador Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a new drug pair safely with a known Anti-Inflammatory? a trial investigates
Knowledge-focused Recruiting nowThis early-stage trial is evaluating the safety and tolerability of a single dose of the investigational drug MT-201 when given alongside infliximab, an approved anti-inflammatory medication. Healthy adults aged 19 to 55 will receive the combination and be monitored for side effe…
Phase 1 • Sponsor: Mirador Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
New drug MT-251 tested in healthy people for first time
Knowledge-focused Recruiting nowThis early-phase trial is testing a new drug, MT-251, in 70 healthy adults aged 19 to 55. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either MT-251 or a placebo, and researchers will monitor for side effects and measure dru…
Phase 1 • Sponsor: Mirador Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New drug MT-201 tested in humans for first time
Knowledge-focused Recruiting nowThis early-phase trial is testing a new drug called MT-201 in 72 healthy adults aged 19 to 55. The main goal is to see if the drug is safe and how the body handles it. Participants will receive either MT-201 or a placebo, and researchers will monitor for side effects and changes …
Phase 1 • Sponsor: Mirador Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC